Targeting complement to treat PNH and other hematologic diseases

Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, explores the use of complement inhibitors in treating paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated hematologic diseases. FDA-approved complement inhibitors for PNH include eculizumab, ravulizumab, pegcetacoplan, and iptacopan. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_eleni_gavriilaki
• #institution_national_and_kapodistrian_university_of_athens
• #event_ash_2023
• #format_interview
• #subject_non_malignant
• #subject_paroxysmal_nocturnal_hemoglobinuria
• #field_treatment
• #field_disease_biology
• #field_immuno_oncology
• #medicines_antibodies
• #medicines_pegcetacoplan
• #medicines_eculizumab
• #medicines_ravulizumab
• #medicines_iptacopan
• #medicines_sutimlimab
• #pnh
• #atypical_hemolytic_uremic_syndrome
• #ahus